1
|
Rossi AH, Ojeda DS, Varese A, Sanchez L, Gonzalez Lopez Ledesma MM, Mazzitelli I, Alvarez Juliá A, Oviedo Rouco S, Pallarés HM, Costa Navarro GS, Rasetto NB, Garcia CI, Wenker SD, Ramis LY, Bialer MG, de Leone MJ, Hernando CE, Sosa S, Bianchimano L, Rios AS, Treffinger Cienfuegos MS, Caramelo JJ, Longueira Y, Laufer N, Alvarez DE, Carradori J, Pedrozza D, Rima A, Echegoyen C, Ercole R, Gelpi P, Marchetti S, Zubieta M, Docena G, Kreplak N, Yanovsky M, Geffner J, Pifano M, Gamarnik AV. Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose. Cell Rep Med 2021; 2:100359. [PMID: 34308389 PMCID: PMC8266543 DOI: 10.1016/j.xcrm.2021.100359] [Citation(s) in RCA: 38] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/06/2021] [Revised: 06/22/2021] [Accepted: 07/05/2021] [Indexed: 10/28/2022]
Abstract
Massive vaccination offers great promise for halting the global COVID-19 pandemic. However, the limited supply and uneven vaccine distribution create an urgent need to optimize vaccination strategies. We evaluate SARS-CoV-2-specific antibody responses after Sputnik V vaccination of healthcare workers in Argentina, measuring IgG anti-spike titers and neutralizing capacity after one and two doses in a cohort of naive or previously infected volunteers. By 21 days after receiving the first dose of the vaccine, 94% of naive participants develop spike-specific IgG antibodies. A single Sputnik V dose elicits higher antibody levels and virus-neutralizing capacity in previously infected individuals than in naive ones receiving the full two-dose schedule. The high seroconversion rate after a single dose in naive participants suggests a benefit of delaying administration of the second dose to increase the number of people vaccinated. The data presented provide information for guiding public health decisions in light of the current global health emergency.
Collapse
Affiliation(s)
- Andres H Rossi
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - Diego S Ojeda
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - Augusto Varese
- Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina
| | - Lautaro Sanchez
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | | | - Ignacio Mazzitelli
- Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina
| | - Anabel Alvarez Juliá
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - Santiago Oviedo Rouco
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - Horacio M Pallarés
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | | | - Natali B Rasetto
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - Corina I Garcia
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - Shirley D Wenker
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - Lila Y Ramis
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - Magalí G Bialer
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - Maria Jose de Leone
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - C Esteban Hernando
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - Santiago Sosa
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - Luciana Bianchimano
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - Antonella S Rios
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | | | - Julio J Caramelo
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - Yesica Longueira
- Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina.,Biobanco de Enfermedades Infecciosas (INBIRS-UBA-CONICET), Caba, Argentina
| | - Natalia Laufer
- Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina.,Biobanco de Enfermedades Infecciosas (INBIRS-UBA-CONICET), Caba, Argentina
| | - Diego E Alvarez
- Instituto de Investigaciones Biotecnológicas, Univ. Nacional de San Martín-CONICET, Buenos Aires, Argentina
| | | | - Dariana Pedrozza
- Hospital Interzonal General de Agudos Dr Pedro Fiorito, Provincia de Buenos Aires, Argentina
| | - Alejandra Rima
- Hospital Interzonal General de Agudos Evita, Provincia de Buenos Aires, Argentina
| | - Cecilia Echegoyen
- Hospital Interzonal General de Agudos Prof. Dr. Rodolfo Rossi, Provincia de Buenos Aires, Argentina
| | - Regina Ercole
- Hospital Interzonal Especializado de Agudos y Crónicos San Juan de Dios, Provincia de Buenos Aires, Argentina
| | - Paula Gelpi
- Hospital Interzonal General de Agudos San Roque, Provincia de Buenos Aires, Argentina
| | - Susana Marchetti
- Hospital Interzonal General de Agudos San Martín, Provincia de Buenos Aires, Argentina
| | - Martín Zubieta
- Hospital de Alta Complejidad El Cruce "Nestor Kirchner," Provincia de Buenos Aires, Argentina
| | - Guillermo Docena
- Instituto de Estudios Inmunológicos y Fisiopatológicos, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, CONICET-CIC, La Plata, Argentina
| | | | - Marcelo Yanovsky
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - Jorge Geffner
- Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina
| | - Marina Pifano
- Ministerio de Salud de Provincia de Buenos Aires, Argentina
| | - Andrea V Gamarnik
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| |
Collapse
|
2
|
Carbajales J, Krishnan D, Principato M, Tomatti A, Paolucci A, Yoo HS, von Wulffen A, Ciampi N, Tepper R, Carradori J, Baranchuk A. Prevalence of Cardiac Arrhythmias and Distal Conduction Disorders in Patients With Chronic Chagas' Disease and Elevated Autoantibodies Against M2 Muscarinic Acetylcholine Receptors. Curr Probl Cardiol 2021; 46:100820. [PMID: 33743434 DOI: 10.1016/j.cpcardiol.2021.100820] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2021] [Accepted: 02/01/2021] [Indexed: 11/17/2022]
Abstract
Chagas' disease (ChD) is a parasitic disease endemic to regions of Latin America and with an increasingly global reach. Up to 30% of patients with ChD develop severe dilated cardiomyopathy, ventricular arrhythmias, conduction disorders and/or sudden cardiac death. Autoantibodies against M2 muscarinic acetylcholine receptors (M2 mAChR) have been implicated in the pathogenesis of ChD. We sought to understand whether there was an association between anti-M2 mAChR autoantibody titers in patients with chronic ChD and the presence of distal cardiac conduction disorders or cardiac arrhythmias. We conducted a cross-sectional study in 79 patients from Argentina and Bolivia with chronic ChD without evident structural heart disease. Autoantibody titers were measured using indirect enzyme-linked immunosorbent assay. Elevated anti-M2 mAChR autoantibody titers were associated with the presence of distal conduction disease but not with cardiac arrhythmias. High anti-M2 mAChR autoantibody levels could assist with identifying early structural heart disease in patients with chronic ChD.
Collapse
Affiliation(s)
- Justo Carbajales
- Cardiovascular Genomic Section, Division of Cardiology, Acute General Hospital, Buenos Aires, Argentina.
| | - Dhruv Krishnan
- Department of Medicine, Queen's University, Kingston Health Sciences Center, Kingston, Ontario, Canada
| | - Mario Principato
- Cardiovascular Genomic Section, Division of Cardiology, Acute General Hospital, Buenos Aires, Argentina
| | - Alejandro Tomatti
- Cardiovascular Genomic Section, Division of Cardiology, Acute General Hospital, Buenos Aires, Argentina
| | - Analía Paolucci
- Cardiovascular Genomic Section, Division of Cardiology, Acute General Hospital, Buenos Aires, Argentina
| | - Hyun Sok Yoo
- Cardiovascular Genomic Section, Division of Cardiology, Acute General Hospital, Buenos Aires, Argentina
| | - Alejandra von Wulffen
- Cardiovascular Genomic Section, Division of Cardiology, Acute General Hospital, Buenos Aires, Argentina
| | - Natalia Ciampi
- Cardiovascular Genomic Section, Division of Cardiology, Acute General Hospital, Buenos Aires, Argentina
| | - Rita Tepper
- Cardiovascular Genomic Section, Division of Cardiology, Acute General Hospital, Buenos Aires, Argentina
| | - Jorge Carradori
- Cardiovascular Genomic Section, Division of Cardiology, Acute General Hospital, Buenos Aires, Argentina
| | - Adrian Baranchuk
- Department of Medicine, Queen's University, Kingston Health Sciences Center, Kingston, Ontario, Canada.
| |
Collapse
|
3
|
Ojeda DS, Gonzalez Lopez Ledesma MM, Pallarés HM, Costa Navarro GS, Sanchez L, Perazzi B, Villordo SM, Alvarez DE, Echavarria M, Oguntuyo KY, Stevens CS, Lee B, Carradori J, Caramelo JJ, Yanovsky MJ, Gamarnik AV. Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina. PLoS Pathog 2021; 17:e1009161. [PMID: 33444413 PMCID: PMC7808630 DOI: 10.1371/journal.ppat.1009161] [Citation(s) in RCA: 52] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2020] [Accepted: 11/13/2020] [Indexed: 12/12/2022] Open
Abstract
We report the emergency development and application of a robust serologic test to evaluate acute and convalescent antibody responses to SARS-CoV-2 in Argentina. The assays, COVIDAR IgG and IgM, which were produced and provided for free to health authorities, private and public health institutions and nursing homes, use a combination of a trimer stabilized spike protein and the receptor binding domain (RBD) in a single enzyme-linked immunosorbent assay (ELISA) plate. Over half million tests have already been distributed to detect and quantify antibodies for multiple purposes, including assessment of immune responses in hospitalized patients and large seroprevalence studies in neighborhoods, slums and health care workers, which resulted in a powerful tool for asymptomatic detection and policy making in the country. Analysis of antibody levels and longitudinal studies of symptomatic and asymptomatic SARS-CoV-2 infections in over one thousand patient samples provided insightful information about IgM and IgG seroconversion time and kinetics, and IgM waning profiles. At least 35% of patients showed seroconversion within 7 days, and 95% within 45 days of symptoms onset, with simultaneous or close sequential IgM and IgG detection. Longitudinal studies of asymptomatic cases showed a wide range of antibody responses with median levels below those observed in symptomatic patients. Regarding convalescent plasma applications, a protocol was standardized for the assessment of end point IgG antibody titers with COVIDAR with more than 500 plasma donors. The protocol showed a positive correlation with neutralizing antibody titers, and was used for clinical trials and therapies across the country. Using this protocol, about 80% of convalescent donor plasmas were potentially suitable for therapies. Here, we demonstrate the importance of providing a robust and specific serologic assay for generating new information about antibody kinetics in infected individuals and mitigation policies to cope with pandemic needs.
Collapse
Affiliation(s)
- Diego S. Ojeda
- Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina
| | | | | | | | | | - Beatriz Perazzi
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Hospital de Clínicas José de San Martin, Departamento de Bioquímica Clínica, Buenos Aires, Argentina
| | | | - Diego E. Alvarez
- Instituto de Investigaciones Biotecnológicas, Universidad Nacional de San Martín-CONICET, Argentina
| | - BioBanco Working Group
- Universidad de Buenos Aires, Facultad de Medicina, Departamento de Microbiología, Parasitología e Inmunología e Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Argentina
| | - Marcela Echavarria
- Unidad de Virologia, Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno” (CEMIC-CONICET), Argentina
| | - Kasopefoluwa Y. Oguntuyo
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America
| | - Christian S. Stevens
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America
| | - Benhur Lee
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America
| | | | | | | | | |
Collapse
|